Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Pay Enzo Biochem $7M to Settle IP Suit

NEW YORK (GenomeWeb) – Enzo Biochem today said that PerkinElmer will pay the firm $7 million as part of a legal settlement reached between the firms last week.

The settlement ends a patent dispute dating back more than a decade. PerkinElmer was one of several defendants named by Enzo in a patent infringement suit initially filed in 2002 in the US District Court for the Southern District of New York. The case surrounded patents licensed to Enzo covering the labeling, hybridizing, and detection of nucleotides.

Specifically, Enzo had alleged that the defendants — including PerkinElmer, Sigma-Aldrich, GE Healthcare, Affymetrix, Orchid Biosciences, Molecular Probes, and Roche — were infringing 15 claims of eight different patents by selling certain reagent kits.

Enzo and PerkinElmer notified the court last Thursday that they had reached an agreement to settle the case and intended to file a notice of dismissal by today.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.